StockNews.AI
BFRI
StockNews.AI
161 days

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

1. Biofrontera will report financial results on March 21, 2025. 2. Conference call scheduled for March 21 at 10:00 AM Eastern Time. 3. Company focuses on dermatological products, especially for skin cancer treatments. 4. Biofrontera is expanding clinical trials for additional acne treatments. 5. Expectations around financial results could impact stock price.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming results may show positive developments, driving investor interest. Historical trends indicate that companies demonstrating growth in earnings tend to see stock price increases.

How important is it?

The announcement of earnings can significantly influence trader sentiment and stock movements. Timely updates are critical for stakeholders, making this news very relevant.

Why Short Term?

Results are imminent; market typically reacts quickly to earnings reports. Previous earnings releases in biotech have caused significant stock volatility.

Related Companies

NVTARADHSTO
WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Call and Webcast Information About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X. Contacts:Investor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com SOURCE: Biofrontera Inc.

Related News